

INDEX

- 5-Fluorouracil (5-FU) anti-cancer agent, dendritic polymer-based delivery systems for, 116
- 60B anti-cancer agent, dendritic polymer-based delivery systems for, 117
- A**
- Active targeting, 32–34, 116, 155
- Anionic dendrimers, 108, 110, 120, 121–122
- Anisotropies, 3, 4, 6, 85, 86–87, 88, 89–90
- Anti-cancer drugs:
- dendritic polymer-based delivery systems for, 116–117
 - intracellular dynamics, 115–119
 - targeting of delivery, 31–32
- Anti-inflammatory drugs, intracellular delivery, 108, 111–115
- Artificial viruses, 26, 27, 30
- B**
- BARCs (bead array counters), 95–96
- Bead array counters (BARCs), 95–96
- Biocompatibility, 26, 27, 29–30, 125
- Biological sensing:
- alternative schemes, 95–97
 - Brownian motion for, 83–84
 - modification of Brownian relaxation, 93–95
 - suppression of Brownian relaxation, 92–93
- Boron anti-cancer agent, dendritic polymer-based delivery systems for, 117, 118
- Branched polymers, 132. *See also* Dendrimers; HBP (hyperbranched polymers)
- Brownian motion:
- calculated relaxation time, 85–86
 - detection, 85–86
 - of magnetic nanoparticles, 83, 84–86
 - particle size dependence, 83, 84–85
 - sensing applications utilizing, 84–86
- Brownian relaxation:
- and ferrofluids, 87–89
 - modification, 93–95, 97
 - open questions, 97–99
- suppression, 92–93
 - time calculations, 85–86
- Bulk polymerization, 143–144, 151
- C**
- C-quadruplexes:
- role of CD spectroscopy, 216–217
 - role of differential scanning calorimetry, 217–219
 - unfolding thermodynamics, 214–219
- Cancer:
- chemotherapy, 115–119
 - delivery of synthetic vaccines for, 156
 - drug localization, 31–32
 - energy transfer therapy mechanisms, 71–77
 - intracellular drug delivery, 115–119
 - radiation therapy, 118–119
 - role of magnetic nanoparticles in diagnosis and treatment, 65–77
 - viscous energy transfer, 73–77
- Carbon nanostructures, 231–232
- Cationic dendrimers, 110, 111, 119, 120, 121, 122–123
- CD. *See* Circular dichroism (CD) spectroscopy
- Cells:
- binding magnetic nanowires to, 12–18
 - chaining process, 14–16
 - delivering genetic material into, 18–19
 - intracellular drug delivery, 108–120
 - magnetic separations, 12–14
 - in microarrays, 14–16
 - multicellular constructs, 14–16
 - normal vs. cancerous, 115–116
 - trapping, 7, 8, 16–17
 - vector-target contact, 34–35
- Centrifugal force, 35
- Chaining:
- cells attached to nanowires, 14–16
 - nanowire segments, 6–7
- Chemical functionalization:
- Ni-Au nanowires, 9–10, 11
 - overview, 8–9
 - and receptor-mediated binding, 9–10
 - selective, 9

- Chemical functionalization (*Continued*)
 spatially resolved, 9
 using biomolecules, 9
- Chemical gels, defined, 134
- Chemically cross-linked nanogels:
 properties, 134–135
 sparsely cross-linked matrixes, 135–136
 synthesizing, 136
- Chemotherapy. *See also* Cancer
 dendritic polymer-based delivery systems for,
 116–117
 intracellular dynamics, 115–119
 targeting of delivery, 31–32
- Circular dichroism (CD) spectroscopy:
 conformational analysis of G-quadruplexes,
 210–211
 oligonucleotide overview, 194–195
 unfolding thermodynamics of C-quadruplexes or
 i-Motifs, 216–217
 unfolding thermodynamics of DNA triplexes,
 201–203
 unfolding thermodynamics of G-quadruplexes,
 211–212
- Cisplatin anti-cancer agent, dendritic polymer-based
 delivery systems for, 117, 118
- Coercivity, defined, 74
- Comb polymers, 132
- Contrast agents, 68, 177, 178, 179
- Core-shell nanogels, 136, 138, 153
- Core-shell structure, defined, 1
- Counterions, differential binding, 195–196
- Cross-linked gels, 132, 134, 147, 148, 149
- Cross-linked polymers, 132, 143, 148
- Cross-linkers, 134, 136, 142, 143, 147–148, 150,
 151, 152
- D**
- Dendri-polymers, 132
- Dendrimers:
 anionic, 108, 110, 120, 121–122
 architecture, 105–106, 107, 108, 109, 114–115,
 124
 biodistribution and safety issues, 121–123
 cationic, 110, 111, 119, 120, 121, 122–123
 cell entry dynamics, 108–115
 convergent growth strategy, 107, 108
 defined, 105
 divergent growth strategy, 107, 108
 future prospects, 123–124
 in gene therapy, 119–120
 in lysosomes, 111
 performance characteristics as nanodelivery
 system, 125
 stepwise synthesis, 107, 108
- Dendrisomes, 124
- Dendritic boxes, 123
- Dendritic polymers. *See also* Dendrimers; HBP
 (hyperbranched polymers)
 architecture, 105–107, 108, 109, 114–115, 124
 biodistribution and safety, 121–123
 cell entry dynamics, 108, 110–111
 characteristics, 106–107
 cytotoxicity profiles, 121
 drug delivery systems for anti-cancer agents,
 116–117
 future prospects, 123–124
 vs. linear polymers, 106–107
 types, 105–106
- Dentriplexes, 119–120
- Deoxyoligonucleotide sequences, 193–194. *See also*
 DNA complexes
- Dermal toxicology, 233
- Differential scanning calorimetry (DSC):
 melting behavior of C-quadruplexes or i-Motifs,
 217–219
 melting behavior of DNA duplexes containing
 loops, 197–200
 melting behavior of DNA triplexes, 203–206
 melting behavior of G-quadruplexes, 212–213
 oligonucleotide overview, 195
- Direct injection, 66, 67
- DNA complexes. *See also* Nucleic acids;
 Oligonucleotides (ODN)
 CD spectroscopy overview, 194–195
 conformation overview, 191–193
 differential binding of counterions and protons,
 195–196
 DSC overview, 195
 experimental protocol, 194
 melting behavior of duplexes containing loops,
 196–200
 melting behavior of G-quadruplexes, 210–214
 melting behavior of triplex and duplex motifs,
 206–209
 temperature-dependent UV spectroscopy
 overview, 194
 unfolding thermodynamics of C-quadruplexes or
 i-Motifs, 214–219
 unfolding thermodynamics of intramolecular
 triplexes, 200–206
- Doxorubicin (DOX) anti-cancer agent, dendritic
 polymer-based delivery systems for, 116, 118
- Drug delivery:
 anti-cancer drugs, 115–119
 anti-inflammatory drugs, 108, 111–115
 biological vs. physical localization methods,
 32–33
 centrifugal targeting, 35

- chemotherapy, 115–119
dendritic polymer architecture, 105–107, 108, 109, 114–115, 124
dendritic polymers for anti-cancer agents, 116–117
gravitational targeting, 35
intracellular, 108–120
list of localization methods, 31–32
magnetic targeting, 35–36, 37, 41–43
microbubbles as carriers, 43–44
nanogel applications, 133, 154–156
oral vs. parenteral administration, 35
synthetic vaccines, 156
- DSC. *See* Differential scanning calorimetry (DSC)
- Duplexes, DNA:
melting behavior of duplexes containing loops, 196–200
melting behavior of motifs, 206–209
- E**
- Einstein, Albert, 83
- Electromagnets, 41–42
- Emulsion polymerization:
gel particle formation, 146–147
gel particle size distribution, 146–147
inverse, 145, 146
microemulsion, 145, 146
overview, 145–146, 153
role of surfactants, 145–146, 147, 153–154
surfactant-free emulsion polymerization, 145, 146
- Endocytosis, 18, 25, 26, 27–29, 110–111, 112, 116, 119, 120, 123
- Energy transfer:
as adjunctive therapy, 72
in cancer therapy, 71–77
magnetic nanoparticle-mediated, 72–75
as primary therapy, 72–75
viscous, 73–77
- Etoposide anti-cancer agent, dendritic polymer-based delivery systems for, 117
- F**
- FA (folic acid), 116, 117, 118, 124
- Ferrofluids:
and Brownian relaxation, 87–89
internal magnetic relaxation, 86–87
magnetic relaxation, 86–91
particle size distribution, 89–91
suppression of Brownian relaxation, 92–93
- Ferromagnetic particles. *See* Ferrofluids
- 5-Fluorouracil (5-FU) anti-cancer agent, dendritic polymer-based delivery systems for, 116
- Focal adhesions, 12, 13
- Folic acid (FA), 116, 117, 118, 124
- Fullerenes, 231, 233
- G**
- G-quadruplexes:
conformational analysis, 210–211
deoxyoligonucleotide sequence, 193
melting behavior, 210–214
role of CD spectroscopy, 210–211
role of differential scanning calorimetry, 212–213
role of temperature-dependent UV spectroscopy, 211–212
- Gel macromodules. *See* Nanogels
- Gel networks, 134, 137, 143, 144, 145, 148, 150, 151–153
- Gel particles, 132, 136, 141, 143–144, 147, 151–154. *See also* Nanogels
- Gene delivery:
dendrimer-gene complex, 111
establishing target cell contact, 34–35
nanowire-assisted, 18–19
useful agents for, 28–29
- Genomes, viral, 25, 26, 29
- GMR sensors, 11, 12
- Gold nanocages, 176, 178
- Gold nanoparticles:
as cancer agents, 174
hybrid, 174, 176
as imaging agents, 176–180
as OCT contrast agent, 178
in optical coherence tomography, 177–178
as optoacoustic contrast agent, 179
overview, 173–174
radioactive, 183–184
spherical, 175
synthesis, 175–176
as therapeutic agents, 174, 180–184
as x-ray contrast agent, 177
- Gold nanoshells, 175, 176, 179, 180, 181
- Graft polymers, 132
- Gravitation, 35
- H**
- H-DNA (Holliday junction), 192, 201
- HBP (hyperbranched polymers):
cell entry dynamics, 111, 112, 113, 114–115, 124
defined, 106
synthesis, 107–108, 109
- Human embryonic kidney cells (HEK293), 18
- Hybrid gold nanoparticles, 174, 176
- Hybrid nanogels, 141–142
- Hydrodynamic diameter, 87, 89–90, 91, 93–94, 97, 152–154

- Hydrodynamic forces, 33, 35, 41, 44, 45, 86
- Hydrogels, 131, 136, 141, 142, 148–149, 155, 156
- Hyperbranched polymers. *See* HBP (hyperbranched polymers)
- Hyperthermia:
 - as adjunctive therapy, 72
 - defined, 71
 - magnetically mediated, 72–75
 - as photothermal therapy, 180–182
 - as primary therapy, 72–75
- Hysteresis curves, 3–4
- Hysteretic heating, as therapeutic energy transfer mechanism, 73, 74

- I**
- I-motifs:
 - deoxyoligonucleotide sequence, 193
 - unfolding thermodynamics, 214–219
- Ibuprofen, 108, 112–114
- Imaging modalities:
 - gold nanoparticles as agents, 174, 175–180
 - imaging magnetic nanoparticles with MRI, 68–69
 - targeting nanoparticles to tumors, 65, 66
- Immunofluorescent staining, 12
- Indomethacin, 113–114
- Inhalation, 232–233
- Interpenetrated nanogels, 137
- Intracellular drug delivery:
 - anti-cancer drugs, 115–119
 - anti-inflammatory drugs, 108, 111–115
 - overview, 108–111
- Intramolecular cross-linking, 142, 148–150
- Inverse emulsion, 145, 146

- J**
- J591 anti-PSMA anti-cancer agent, dendritic polymer-based delivery systems for, 117

- L**
- Linear polymers, 106–107, 132
- Lipoplexes, 29
- Liposome-modified physically cross-linked nanogels, 137–140
- Lysosomes, 111, 112, 115, 119

- M**
- Macrogels, 131
- Macroscopic gels, 143, 150–151
- Magnetic biosensing, 10–12
- Magnetic drug targeting, 35–36, 37, 41–43
- Magnetic field sensors, 11, 69–71
- Magnetic hysteresis loop, 73, 74
- Magnetic microbubbles, 43–45, 46, 47, 48
- Magnetic nanoparticles. *See also* Nanowires
 - in cancer diagnosis and treatment, 65–77
 - energy transfer therapy mechanisms, 71–77
 - internal magnetic relaxation, 86–87
 - as labels for biological sensing, 84
 - localization with SQUID sensor arrays, 69–71
 - relaxation through mechanical motion, 87–89
 - role of gold in, 65–66
 - rotational Brownian motion of, 83–84
 - saturating magnetization, 93
- Magnetic particles. *See* Magnetic nanoparticles; Nanoparticles; Nanowires
- Magnetic relaxation. *See also* Brownian relaxation
 - internal, 86–87
 - through mechanical motion, 87–89
- Magnetic resonance imaging (MRI):
 - combined with optical imaging, 176–177
 - contrast agents, 68, 177
 - imaging magnetic nanoparticles, 68–69
 - measuring neuronal currents, 68–69
 - vs. SQUID sensor arrays, 69–71
 - thermometry, 77
- Magnetic susceptibility, 88–89, 90, 91–92, 93, 94
- Magnetic trapping, 7, 8
- Magnetic viruses, 98–99
- Magnetically mediated hyperthermia (MMH), 72–75
- Magnetite particles, 86, 87, 90, 91, 93–95
- Magnetofection:
 - carrier materials, 36–37
 - defined, 35
 - overview, 35–36
 - synthesizing nanomaterials, 37–43
 - vs. transfection, 39–40
- Mechanical targeting, 67
- Methotrexate (MTX) anti-cancer agent, dendritic polymer-based delivery systems for, 116, 118
- Micelles:
 - compared with dendrimers, 123
 - hydrophobic, 201
 - for nanogels, 140–141
 - performance characteristics as nanodelivery system, 125
- Microbubbles, 43–45, 46, 47, 48
- Microemulsion, 145, 146
- Microgels, 131, 132
- Micromagnets:
 - arranging cells into, 15–18
 - interaction with nanowires, 6, 7–8
 - patterning, 6, 7, 10, 11, 15–18
- Microspheres, 156

- MMH (magnetically mediated hyperthermia), 72–75
 MRI. *See* Magnetic resonance imaging (MRI)
- N**
- Nanocapsules, 133
- Nanogels:
 advanced features, 133
 applications, 132–133
 biomimetic, 132–133
 chemically cross-linked, 134–137
 classification, 133–142
 combined networks, 137
 conversion of macroscopic gels to, 143, 150–151
 core-shell, 136, 138, 153
 defined, 131, 132
 drug delivery applications, 133, 154–156
 ideal intramolecular cross-linking technique, 142, 148–150
 interpenetrated, 137
 micellar, 140–141
 molecular structure, 132
 and pH, 133, 134, 136, 138–139, 140, 142, 153
 physically cross-linked, 137–142
 polyampholytic, 137
 properties, 151–154
 in regenerative medicine, 156
 self-oscillating, 132–133
 silent features, 156–157
 simultaneous cross-linking polymerization, 142, 143–148
 size range, 132
 smart, 136
 swelling property, 133, 151, 152
 synthesizing, 136, 142–151
 types of linkages, 134–142
- Nanomaterials:
 core/shell type, 37
 synthesizing for magnetofection, 37–43
 toxicology, 228–234
- Nanoparticles. *See also* Magnetic nanoparticles;
 Nanowires
 colloidal clustering, 38–40
 concentrating, 67
 gold, 173–184
 hybrid, 174, 176
 localizing concentrations, 67–71
 performance characteristics as nanodelivery system, 125
 targeting, 67, 174
 viruses as, 24–25
- Nanoshells, 175, 176, 179, 180, 181
- Nanospheres, 133
- Nanotoxicology:
 and carbon nanostructures, 231–232
 effect of surface charge, 231
 effect of surface chemistry, 230–231
 gastrointestinal issues, 233–234
 inhalation issues, 232–233
 overview, 227–228
 parameters, 228–229, 230
 role of reactive oxygen species, 229–230
 toxicity mechanisms, 229–232
in vivo studies, 232–234
- Nanotubes, 229, 230, 231–232, 233–234
- Nanowires:
 applying forces to cells, 12–18
 biomagnetic applications, 4
 biosensing applications, 11–12
 chaining dynamics, 7
 chemical functionalization, 8–9
 fabrication, 3
 ferromagnetic nickel, 3
 in gene delivery, 18–19
 in gene transfection experiments, 18, 19
 genetic immunization applications, 18–19
 hysteresis curves, 3–4
 internalizing, 12, 13, 14
 in liquid suspensions, 6
 magnetic moments, 6
 magnetic properties, 3–4, 5
 and micromagnet cell arrays, 15–18
 multisegment, 3, 4, 9
 Ni-Au, 9–10, 11, 18
 optical properties, 4, 6
 physical properties, 3–6
 single-segment, 3, 8–9
 and strong local fields, 7–8
 tunability, 12
 velocity, 6–7
- Near-infrared (NIR) radiation, 182
- Néel relaxation, 86, 87, 89, 92, 97
- Nonviral vectors, 25–26, 27, 28, 29, 30, 40, 124, 126
- Nuclear transport, 26, 27, 29, 119
- Nucleic acids:
 artificial virus-like delivery systems, 26, 27, 30
 compaction, 26, 28
 conformation of DNA complexes, 191–193
 delivery by magnetic force, 35–43
 delivery into cells, 24
 feasibility of magnetic targeting, 40–41
 and gene therapy, 30, 120
 localizing delivery, 31–32
 microbubble delivery, 44
 role of vector targeting in delivery, 31–32, 34

Nucleic acids (*Continued*)
 shuttles for delivery, 24–25
 for therapeutic purposes, 24
 triplexes, 192

O

OAT (optoacoustic tomography), 178–180
 Ohmic heating, as therapeutic energy transfer
 mechanism, 72, 73, 76
 Oligonucleotides (ODN). *See also* DNA complexes
 antisense vs. free, 39, 120
 CD spectroscopy, 194–195
 differential binding of counterions and protons,
 195–196
 differential binding of protons in the helix-coil
 transitions of C₃TA₂, 219
 differential scanning calorimetry, 197–200
 experimental protocol, 194
 helical and coil states, 195–196
 and nanogels, 136
 synthesis, 193–194
 temperature-dependent UV spectroscopy, 197
 Optical coherence tomography (OCT), 177–178
 Optical imaging, 176–180
 Optoacoustic tomography (OAT), 178–180
 Oral drug administration, 35

P

PAMAM (polyamidoamine):
 biodistribution and safety, 121, 122, 123
 cell entry dynamics, 108, 110–111, 112, 113,
 114–115
 defined, 106
 as delivery system for anti-cancer agents,
 116–117
 Parenteral drug administration, 35
 Passive targeting, 32, 34, 67, 155
 PAT (photoacoustic tomography), 178–180, 181
 Patterning, 6, 7, 10, 11, 15–18
 PEI (polyethylenimine), 28, 31, 34, 35, 40, 136,
 138, 144
 Peptides, 28, 29
 PH, and nanogels, 133, 134, 136, 138–139, 140,
 142, 153
 Photoacoustic tomography (PAT), 178–180, 181
 Photothermal therapy, 180–182
 Physical gels, defined, 133–134
 Physically cross-linked nanogels:
 hybrid, 141–142
 liposome modified, 137–140
 micellar, 140–141
 Polyamidoamine. *See* PAMAM (polyamidoamine)

Polyampholytic nanogels, 137
 Polyethylenimine (PEI), 28, 31, 34, 35, 40, 136,
 138, 144
 Polyglycerols, hyperbranched, 108, 112
 Polymeric gels. *See also* Nanogels
 classification, 133–134
 defined, 131
 molecular structure, 132
 producing, 144, 147
 Polymers, tree-like architecture, 105–106. *See also*
 HBP (hyperbranched polymers)
 Proton sponge hypothesis, 28
 Pseudoknots, 196, 197, 198–199, 200

R

Radiation polymerization, 147, 149–150
 Radiation therapy, 118–119
 Radioactive gold nanoparticles, 183–184
 Radiotherapy, 183–184
 Reactive oxygen species (ROS), 229–230
 Receptor-ligand interactions, 25, 26–27, 33, 35, 44
 Receptor-mediated self-assembly of nanowires,
 9–10, 11
 Recombinant retroviruses, 25
 Regenerative medicine, nanogels in, 156
 Remanent magnetization, 3–4, 11, 12, 74, 75, 93
 Retroviruses, 25
 Reynolds number, 6
 Roentgen, Wilhelm, 227
 ROS (reactive oxygen species), 229–230
 Rotational Brownian motion:
 calculated relaxation time, 85–86
 detection, 85–86
 of magnetic nanoparticles, 83, 84–86
 sensing applications utilizing, 84–86

S

Simultaneous cross-linking polymerization:
 bulk method, 143–144
 defined, 143
 emulsion method, 145–147
 nonconventional methods, 147–148
 solution method, 144–145
 suspension method, 147
 as type of nanogel synthesis, 142
 60B anti-cancer agent, dendritic polymer-based
 delivery systems for, 117
 Solution polymerization, 144–145
 SQUID (superconducting quantum interference
 device) sensors, 68, 69–71
 Star polymers, 132
 Steroidal drugs, 114–115
 Stray magnetic fields, 95, 96–97

- Superconducting quantum interference devices. *See* SQUID (superconducting quantum interference device) sensors
- Surface chemistry, 230–231
- Surfactant-free emulsion polymerization, 145, 146
- Surfactants, 145–146, 147, 153–154
- Suspension polymerization, 147
- Synthetic vaccines, delivering, 156
- T**
- Targeting:
 - active vs. passive, 32–34
 - and cancer treatment, 31–32, 67, 174
 - and drug delivery, 35–36, 37, 41–43
 - role in nucleic acid delivery, 31–32, 34
- Taxol anti-cancer agent, dendritic polymer-based delivery systems for, 117
- Temperature. *See* Thermal monitoring
- Temperature-dependent UV spectroscopy:
 - melting behavior of DNA duplexes containing loops, 197
 - melting techniques of C₃TA₂, 215–216
 - oligonucleotide overview, 194
 - unfolding thermodynamics of G-quadruplexes, 211–212
- Thermal monitoring, 77
- Toxicology. *See* Nanotoxicology
- Transfection:
 - efficiencies, 28, 34–35, 45, 48, 119
 - vs. magnetofection, 39–40
 - nonviral, 30
 - protocols, 34
 - transfecting agents, 120
- Transferrin, 18
- Triplexes, DNA:
 - background, 192
 - deoxyoligonucleotide sequence, 193
 - melting behavior of motifs, 206–209
 - role of CD spectroscopy, 201–203
 - role of differential scanning calorimetry, 203–206
 - unfolding thermodynamics, 200–206
- Tumors. *See* Cancer
- U**
- Ultrasound, in localized delivery, 43–45, 46, 47, 48
- Ultrasound/microwave polymerization, 147, 148
- UV polymerization, 147, 148
- UV spectroscopy. *See* Temperature-dependent UV spectroscopy
- V**
- Vaccines, synthetic, delivering, 156
- Vectors:
 - nonviral, 25–26, 27, 28, 29, 30, 40, 124, 126
 - targeting in nucleic acid delivery, 31–32, 34
 - viral, 24–25
- Viral genomes, 25, 26
- Viral vectors, 24–25
- Viruses:
 - artificial, 26, 27, 30
 - binding to cell surfaces, 25
 - biocompatibility, 26, 27, 29–30
 - entry into cells, 25
 - infectivity functions, 24–25
 - magnetic, 98–99
 - membrane-coated, 25
 - as nanoparticles, 24–25
- Viscous energy transfer, 73–77
- X**
- X-ray contrast agents, 177
- X-ray therapy, 183
- X-rays, public reaction to, 227

